Cargando…

Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis

OBJECTIVES: This study aimed to use evidence mapping to provide an overview of immune checkpoint inhibitors (ICIs) as perioperative treatments for non-small cell lung cancer (NSCLC) and to identify areas of this field where future research is most urgently needed. METHODS: Multiple databases (PubMed...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Yunfeng, Lei, Jie, Huang, Wan, Wang, Jian, Guo, Haihua, Lv, Feng, Kang, Shuhong, Lan, Ke, Jiang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172597/
https://www.ncbi.nlm.nih.gov/pubmed/37182179
http://dx.doi.org/10.3389/fonc.2023.1092663
_version_ 1785039640882839552
author Ni, Yunfeng
Lei, Jie
Huang, Wan
Wang, Jian
Guo, Haihua
Lv, Feng
Kang, Shuhong
Lan, Ke
Jiang, Tao
author_facet Ni, Yunfeng
Lei, Jie
Huang, Wan
Wang, Jian
Guo, Haihua
Lv, Feng
Kang, Shuhong
Lan, Ke
Jiang, Tao
author_sort Ni, Yunfeng
collection PubMed
description OBJECTIVES: This study aimed to use evidence mapping to provide an overview of immune checkpoint inhibitors (ICIs) as perioperative treatments for non-small cell lung cancer (NSCLC) and to identify areas of this field where future research is most urgently needed. METHODS: Multiple databases (PubMed, EMBASE, Cochrane Library, and Web of Science) were searched to identify clinical trials published up to November 2021 that examined the effect of perioperative ICIs for perioperative treatment of NSCLC. Study design, sample size, patient characteristics, therapeutic regimens, clinical stages, short-term and long-term therapeutic outcomes, surgery associated parameters, and therapeutic safety were examined. RESULTS: We included 66 trials (3564 patients) and used evidence mapping to characterize the available data. For surgery associated outcomes, sixty-two studies (2480 patients) provided complete information regarding the use of surgery after neoadjuvant immunotherapy and data on R0 resection were available in 42 studies (1680 patients); for short-term clinical outcomes, 57 studies (1842 patients) evaluated pathologic complete response (pCR) after neoadjuvant immunotherapy and most of included studies achieved pCR in the range of 30 to 40%; for long-term clinical outcomes, 15 studies (1932 patients) reported DFS, with a median range of 17.9-53.6 months; and only a few studies reported the safety profiles of perioperative immunotherapies. CONCLUSION: Our evidence mapping systematically summarized the results of all clinical trials and studies that examined ICIs as perioperative treatments for NSCLC. The results indicated more studies that evaluate long-term patient outcomes are needed to provide a stronger foundation for the use of these treatments.
format Online
Article
Text
id pubmed-10172597
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101725972023-05-12 Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis Ni, Yunfeng Lei, Jie Huang, Wan Wang, Jian Guo, Haihua Lv, Feng Kang, Shuhong Lan, Ke Jiang, Tao Front Oncol Oncology OBJECTIVES: This study aimed to use evidence mapping to provide an overview of immune checkpoint inhibitors (ICIs) as perioperative treatments for non-small cell lung cancer (NSCLC) and to identify areas of this field where future research is most urgently needed. METHODS: Multiple databases (PubMed, EMBASE, Cochrane Library, and Web of Science) were searched to identify clinical trials published up to November 2021 that examined the effect of perioperative ICIs for perioperative treatment of NSCLC. Study design, sample size, patient characteristics, therapeutic regimens, clinical stages, short-term and long-term therapeutic outcomes, surgery associated parameters, and therapeutic safety were examined. RESULTS: We included 66 trials (3564 patients) and used evidence mapping to characterize the available data. For surgery associated outcomes, sixty-two studies (2480 patients) provided complete information regarding the use of surgery after neoadjuvant immunotherapy and data on R0 resection were available in 42 studies (1680 patients); for short-term clinical outcomes, 57 studies (1842 patients) evaluated pathologic complete response (pCR) after neoadjuvant immunotherapy and most of included studies achieved pCR in the range of 30 to 40%; for long-term clinical outcomes, 15 studies (1932 patients) reported DFS, with a median range of 17.9-53.6 months; and only a few studies reported the safety profiles of perioperative immunotherapies. CONCLUSION: Our evidence mapping systematically summarized the results of all clinical trials and studies that examined ICIs as perioperative treatments for NSCLC. The results indicated more studies that evaluate long-term patient outcomes are needed to provide a stronger foundation for the use of these treatments. Frontiers Media S.A. 2023-04-27 /pmc/articles/PMC10172597/ /pubmed/37182179 http://dx.doi.org/10.3389/fonc.2023.1092663 Text en Copyright © 2023 Ni, Lei, Huang, Wang, Guo, Lv, Kang, Lan and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ni, Yunfeng
Lei, Jie
Huang, Wan
Wang, Jian
Guo, Haihua
Lv, Feng
Kang, Shuhong
Lan, Ke
Jiang, Tao
Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
title Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
title_full Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
title_fullStr Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
title_full_unstemmed Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
title_short Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
title_sort systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172597/
https://www.ncbi.nlm.nih.gov/pubmed/37182179
http://dx.doi.org/10.3389/fonc.2023.1092663
work_keys_str_mv AT niyunfeng systematicreviewoftheperioperativeimmunotherapyinpatientswithnonsmallcelllungcancerevidencemappingandsynthesis
AT leijie systematicreviewoftheperioperativeimmunotherapyinpatientswithnonsmallcelllungcancerevidencemappingandsynthesis
AT huangwan systematicreviewoftheperioperativeimmunotherapyinpatientswithnonsmallcelllungcancerevidencemappingandsynthesis
AT wangjian systematicreviewoftheperioperativeimmunotherapyinpatientswithnonsmallcelllungcancerevidencemappingandsynthesis
AT guohaihua systematicreviewoftheperioperativeimmunotherapyinpatientswithnonsmallcelllungcancerevidencemappingandsynthesis
AT lvfeng systematicreviewoftheperioperativeimmunotherapyinpatientswithnonsmallcelllungcancerevidencemappingandsynthesis
AT kangshuhong systematicreviewoftheperioperativeimmunotherapyinpatientswithnonsmallcelllungcancerevidencemappingandsynthesis
AT lanke systematicreviewoftheperioperativeimmunotherapyinpatientswithnonsmallcelllungcancerevidencemappingandsynthesis
AT jiangtao systematicreviewoftheperioperativeimmunotherapyinpatientswithnonsmallcelllungcancerevidencemappingandsynthesis